<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004012</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#20-001573</org_study_id>
    <nct_id>NCT05004012</nct_id>
  </id_info>
  <brief_title>Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility</brief_title>
  <official_title>AnX/Ankon Navicam Magnetically Controlled Capsule Endoscopy Feasibility Study in Gastric Motility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study to assess the utility of magnetically controlled capsule&#xD;
      endoscopy in the evaluation of gastroparesis and functional dyspepsia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroparesis and functional dyspepsia can both present with abdominal pain, dyspepsia,&#xD;
      nausea, emesis, or early satiety. Gastroparesis is a syndrome defined as delayed gastric&#xD;
      emptying. Functional dyspepsia is a symptom-based diagnosis in which the pathophysiology is&#xD;
      multifactorial. Delayed gastric emptying is present in 25-35% of patients with functional&#xD;
      dyspepsia. The study investigators propose the Navicam magnetically controlled capsule&#xD;
      endoscopy (MCCE) system as a potential new method of evaluating gastric motility disorders.&#xD;
      The MCCE is FDA approved for visualization of the stomach. The ability to visualize gastric&#xD;
      peristalsis in real time, without interference from an endoscope, has never been&#xD;
      demonstrated. The MCCE system could allow physicians to evaluate gastric motility with a test&#xD;
      that has clear advantages over the current methods: it is fast, non-invasive, and has no&#xD;
      radiation exposure, has artificial intelligence (AI) capabilities, while at the same time&#xD;
      provides a visual assessment of the gastric anatomy. In this pilot feasibility study, the&#xD;
      study investigators plan to enroll 5 male and female adult healthy volunteers, 5 male and&#xD;
      female patients with gastroparesis, 5 male and female patients with functional dyspepsia&#xD;
      (epigastric pain syndrome and/or postprandial distress syndrome with or without gastric&#xD;
      emptying delay), and 2 patients with gastroparesis who have undergone a G-POEM procedure. The&#xD;
      study investigators will compare gastric motor patterns in the different sections of the&#xD;
      stomach and symptoms during fasting and a sham meal between groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Four groups of participants will be studied: gastroparesis, functional dyspepsia, gastroparesis patients s/p G-POEM, and healthy controls.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and direction of contractions</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Physiologic parameter measuring the frequency and direction of stomach contractions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and location of luminal transit markers in the antrum, fundus, and overall</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Physiologic parameter measuring the number and location of luminal transit markers in the stomach</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Largest diameter of the pylorus</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Physiologic parameter measuring the diameter of the pylorus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyspepsia Severity Scale symptom ratings at baseline and during the study at timepoints with discomfort if present.</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Evaluating the dyspepsia Severity Scale symptom ratings (range of score 0-20) at baseline and during the study at timepoints with discomfort if present.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedure related adverse events</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Procedure related adverse events during or after the study session</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No diagnosis of gastroparesis, functional dyspepsia, or prior G-POEM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastroparesis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with a diagnosis of gastroparesis meeting the inclusion criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Functional Dyspepsia</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with a diagnosis of functional dyspepsia meeting the inclusion criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-POEM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who received a G-POEM procedure meeting the inclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetically Controlled Capsule Endoscopy</intervention_name>
    <description>This is a diagnostic device for gastric disorders used to diagnose mucosal abnormalities. In this study it will be evaluated for use in gastric motility.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Functional Dyspepsia</arm_group_label>
    <arm_group_label>G-POEM</arm_group_label>
    <arm_group_label>Gastroparesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Must meet one of the following categories:&#xD;
&#xD;
          1. Gastroparesis&#xD;
&#xD;
             Meets diagnostic criteria for gastroparesis:&#xD;
&#xD;
               1. Evidence of delayed gastric emptying documented with a standard 2 hour or 4 hour&#xD;
                  gastric emptying scintigraphy exam&#xD;
&#xD;
               2. Absence of mechanical obstruction&#xD;
&#xD;
               3. Exhibits cardinal symptoms of early satiety, post-prandial fullness, nausea,&#xD;
                  vomiting, bloating, and upper abdominal pain&#xD;
&#xD;
             Gastrointestinal cardinal symptom index (GCSI) score &gt; 0 (i.e., the presence of at&#xD;
             least mild severity of &gt;1 of 3 symptoms of nausea/vomiting, postprandial&#xD;
             fullness/early satiety, and/or bloating).&#xD;
&#xD;
          2. Functional Dyspepsia&#xD;
&#xD;
             Meets Rome IV diagnostic criteria for functional dyspepsia:&#xD;
&#xD;
               1. Criteria fulfilled for the last 3 months with symptom onset at least six months&#xD;
                  prior to diagnosis&#xD;
&#xD;
               2. No evidence of organic, systemic, or metabolic disease that is likely to explain&#xD;
                  the symptoms on routine investigations (including at upper endoscopy)&#xD;
&#xD;
               3. Meet criteria for Epigastric pain syndrome and/or Postprandial distress syndrome&#xD;
&#xD;
             Epigastric Pain Syndrome At least 1 of the following symptoms at least 1 day per week&#xD;
&#xD;
               1. Bothersome epigastric pain&#xD;
&#xD;
               2. Bothersome epigastric burning&#xD;
&#xD;
             Postprandial Distress Syndrome At least 1 of the following symptoms at least 3 days&#xD;
             per week&#xD;
&#xD;
               1. Bothersome postprandial fullness&#xD;
&#xD;
               2. Bothersome early satiation&#xD;
&#xD;
          3. G-POEM&#xD;
&#xD;
               1. The G-POEM procedure must have been performed at least 4 weeks prior to&#xD;
                  screening.&#xD;
&#xD;
               2. GCSI score is &lt; 3 which correlates to mild or less symptom severity.&#xD;
&#xD;
          4. Controls&#xD;
&#xD;
        None of the above conditions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Another active disorder or treatment which could explain or contribute to symptoms in&#xD;
             the opinion of the Investigator (including but not limited to gastric malignancy,&#xD;
             neurological disorder, or heavy doses of strong anticholinergics).&#xD;
&#xD;
          2. Gastrectomy, fundoplication, vagotomy, bariatric surgery, post-surgical cause of&#xD;
             gastroparesis, or gastric stimulation device surgically implanted within the last&#xD;
             year. Prior G-POEM procedure for gastroparesis is allowed for the group of post-G-POEM&#xD;
             study subjects.&#xD;
&#xD;
          3. Dysphagia, swallowing disorder&#xD;
&#xD;
          4. Suspected bowel obstruction or perforation&#xD;
&#xD;
          5. Gastric or parenteral feeding within 4 weeks of screening&#xD;
&#xD;
          6. Pregnancy or nursing&#xD;
&#xD;
          7. History of an eating disorder within 2 years of screening&#xD;
&#xD;
          8. Recent history (within six months of screening) of Alcohol Use Disorder or Substance&#xD;
             Use Disorder as defined in DSM-5.&#xD;
&#xD;
          9. Uncontrolled thyroid disease&#xD;
&#xD;
         10. Unstable cardiac, respiratory, hepatic or renal disease&#xD;
&#xD;
         11. Evidence of uncontrolled blood glucose (including HbA1C &gt;9 or metabolic crisis in past&#xD;
             60 days).&#xD;
&#xD;
         12. Use of prohibited medication or medication with anti-nausea, antiemetic,&#xD;
             neuromodulating, or prokinetic effect within 2 weeks of the screening visit EXCEPT&#xD;
             when administered on a stable daily dosing schedule (stable for at least 1 month prior&#xD;
             to the screening visit).&#xD;
&#xD;
         13. Use of as needed or daily opioids within the past 1 month.&#xD;
&#xD;
         14. Pyloric injection of neurotoxins (e.g. botulinum type A or B) within 3 months of the&#xD;
             Screening visit.&#xD;
&#xD;
         15. Altered mental status (e.g., hepatic encephalopathy) that limits the ability to&#xD;
             swallow a capsule&#xD;
&#xD;
         16. Expected to have Magnetic Resonance Imaging (MRI) examination within 30 days.&#xD;
&#xD;
         17. No reliable contact information - no phone, no permanent address.&#xD;
&#xD;
         18. Pacemaker or ICD&#xD;
&#xD;
         19. Inability to avoid using the bathroom for urination and/or bowel movements for the&#xD;
             duration of the study.&#xD;
&#xD;
         20. Metal Implant (ie metal hip arthroplasty, surgical mesh, coronary or arterial stent)&#xD;
&#xD;
         21. Prior bowel surgery&#xD;
&#xD;
         22. Severe claustrophobia&#xD;
&#xD;
         23. Any other reason as determined by the Investigator which may lead to an unfavorable&#xD;
             risk-benefit of study participation, may interfere with study compliance, or may&#xD;
             confound study results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Chang, MD</last_name>
    <phone>(310) 206-0192</phone>
    <email>linchang@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dean Ehrlich, MD</last_name>
    <phone>(310) 206-0192</phone>
    <email>dsehrlich@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin Chang, MD</last_name>
      <phone>310-206-0192</phone>
      <email>linchang@mednet.ucla.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lacy BE, Talley NJ, Locke GR 3rd, Bouras EP, DiBaise JK, El-Serag HB, Abraham BP, Howden CW, Moayyedi P, Prather C. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012 Jul;36(1):3-15. doi: 10.1111/j.1365-2036.2012.05128.x. Epub 2012 May 16. Review.</citation>
    <PMID>22591037</PMID>
  </reference>
  <reference>
    <citation>Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013 Jan;108(1):18-37; quiz 38. doi: 10.1038/ajg.2012.373. Epub 2012 Nov 13.</citation>
    <PMID>23147521</PMID>
  </reference>
  <reference>
    <citation>Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, Tack J. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003 Jul 1;18(1):141-50.</citation>
    <PMID>12848636</PMID>
  </reference>
  <reference>
    <citation>Revicki DA, Rentz AM, Tack J, Stanghellini V, Talley NJ, Kahrilas P, De La Loge C, Trudeau E, Dubois D. Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clin Gastroenterol Hepatol. 2004 Sep;2(9):769-77.</citation>
    <PMID>15354277</PMID>
  </reference>
  <reference>
    <citation>Carbone F, Vanuytsel T, Tack J. Analysis of Postprandial Symptom Patterns in Subgroups of Patients With Rome III or Rome IV Functional Dyspepsia. Clin Gastroenterol Hepatol. 2020 Apr;18(4):838-846.e3. doi: 10.1016/j.cgh.2019.07.053. Epub 2019 Aug 5.</citation>
    <PMID>31394286</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Lin Chang, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

